Talis Biomedical effects 1-for-15 reverse stock split to regain Nasdaq compliance

Talis Biomedical Corp

Reverse split effective July 5, 2023; shares reduce from ~26.9M to ~1.8M.
Stock begins trading on post-split basis on Nasdaq on July 6 under symbol TLIS.
No fractional shares; any fractional interest rounded up to one whole share.
CUSIP number changed to 87424L207; par value unchanged at $0.0001.
Split intended to raise per-share price to satisfy Nasdaq minimum bid requirement.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Talis Biomedical Corp: Filed a certificate of amendment to effect a 1-for-15 reverse stock split of common stock (effective 2023-07-05).

Change: charter amendment
Effective: 2023-07-05

Exact text from the filing

On June 30, 2023, Talis Biomedical Corporation (the “Company”) filed a certificate of amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”), with the Secretary of State of the State of Delaware to effect a 1-for-15 reverse stock split of the shares of the Company’s common stock, par value $0.0001 per share, effective as of 5:00 p.m., Eastern Time, on July 5, 2023

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0000950170-23-031488

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.